OSE Immunotherapeutics and Oncology Physician Network GERCOR Announce Submission of a Clinical Trial Application to Evaluate Tedopi® in Combination with Nivolumab in Pancreatic Cancer

The Phase 2 clinical trial of Tedopi® in pancreatic cancer will be sponsored by the oncology group GERCOR…

 

OSE Immunotherapeutics to Present at the 18th Annual Biotech in Europe Investor Forum, Oct. 4-5, 2018, Congress Center Basel

Alexis Peyroles, chief executive officer, will present an overview of the Company’s business and will be available to participate in one-on-one meetings with investors…

 

OSE Immunotherapeutics Announces Issuance of a European Patent Protecting FR104, CD28-Antagonist Immunotherapy

The patent covers therapeutic applications of FR104 in Europe in autoimmune diseases,
chronic inflammatory diseases and graft applications through 2031…

 

OSE Immunotherapeutics Reports First-Half 2018 Results and Provides a Corporate Update

Key Highlights:_Entered into a global immuno-oncology agreement …

 

 

OSE Immunotherapeutics Publishes New Efficacy Data on FR104, CD28-Antagonist Immunotherapy

FR104 shown to be efficacious in a preclinical bone marrow transplant model; Research published in the Journal of Clinical Investigation conducted with multiple international expert partners…

 

 

 

OSE Immunotherapeutics Receives a €435,000 Translational Research Grant to Develop Precision Medicine Targeting for Tedopi®

Funding through the Eurostars European Programme, led in France by Bpifrance…

OSE Immunotherapeutics Receives IDMC Approval to Continue “Atalante 1” Phase 3 NSCLC Clinical Trial of Tedopi®

Trial in Non-Small Cell Lung Cancer (NSCLC) Patients After Immune Checkpoint Inhibitor Failure; Checkpoint Inhibitor Failures Is an Unmet Need in Non-Small Cell Lung Cancer Patient Population…

OSE Immunotherapeutics Announces Results of 2018 Annual Shareholder Meeting

The results of each resolution voted can be found on the Company’s website in the “Investor Relations – Annual General Meeting” section (http://ose-immuno.com/documentation/assemblee-generale/)… 

OSE Immunotherapeutics to Present at 4th Annual Immuno-Oncology: BD&L and Investment Forum Forum to be held in Chicago, IL, on June 1, 2018

Alexis Peyroles, chief executive officer, will provide a Company update, including recent accomplishments and future plans, at the upcoming 4th Annual Immuno-Oncology: BD&L and Investment Forum…

 

OSE Immunotherapeutics Presents New Data on OSE-127 at the American Association of Immunologists (AAI) Annual Meeting

OSE-127 significantly decreases inflammation in colon biopsies from patients with inflammatory bowel diseases…